Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

RhoA-induced suppression of the HSR decreases cell stress resistance and induces cell death via apoptosis. by Roelien A. M. Meijering (217816)

Dex increases migration independently of WNT5A/Frizzled-5 interaction. by Martin Crozier (13804275)

Sirt5 KO induces increased lysine succinylation and decreased ATP synthase activity in mouse heart mitochondria. by Mengli Zhang (6331172)

Activin A decreases MPTP and LPS-induced inflammation. by Sandy Stayte (728461)

“…<p>Stereological quantification of the left SNpc demonstrated activin A significantly decreased the number of GFAP-immunoreactive cells (A) and Iba1-immunoreactive cells (B) in the SNpc following MPTP. …”

The effect of novel synthetic communities on plant shoot Pi content can be predicted by an NN. by Sur Herrera Paredes (674875)

“…<p>(<b>A</b>) Schematic representation of the NN defined and applied for predictions. …”

Grey matter concentration decreases for (A) tinnitus duration. by Sven Vanneste (202029)

“…<p>Grey matter decrease projected onto a T1-weighted image. Maximum intensity projection with a threshold of <i>p</i> < .001 (uncorrected) at both voxel and cluster level. …”

siRNA-mediated depletion of CUL5 in HUVEC prevents thalidomide-dependent decrease in cellular proliferation. by Bryan Kunkler (5204327)

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Decreased expression of genes related with cell cycle and growth signaling in the lung tissue during infection with HeV and NiV-B. by Alberto J. Leon (132911)

BoNT/A (3.5 U/kg) decreases dural extravasation in IoNC-injured rats which is prevented by intraganglionic colchicine. by Boris Filipović (336089)

Dose-dependent inhibition of V-ATPase with Bafilomycin A1 decreases LysoTracker Red fluorescence and increases Lyso-pHluorin fluorescence. by Yarden Golan (5924594)

BoNT/A (3.5 U/kg) decreases IoNC-induced mechanical allodynia which is prevented by intraganglionic colchicine pretreatment. by Boris Filipović (336089)

Table 5_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

“…The ACM rates were 22.5% at 30 days and rose to 26.0% at 90 days. Multivariable Cox regression showed that, after full adjustment for potential confounders, every 2-unit decrease in PNI was associated with a 10% higher 30-day mortality hazard (HR = 1.10, 95% CI = 1.05–1.15, p < 0.001) and a 9% higher 90-day mortality hazard (HR = 1.09, 95% CI = 1.04–1.14, p < 0.001). …”

Kcnk5b requires CaMKK for growth and SHH/<i>shha</i> expression. by Xiaowen Jiang (8291814)

Treatment with wt- or S360A-(A)PC decreases infarct area. by Karin C. A. A. Wildhagen (599651)